Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  SLU-PP-915

Research reference — not for sale

SLU-PP-915

F

lead outcome

Endurance / exercise capacity (the marketed…

grades vary by outcome ↓

Small molecule (non-peptide)⚠ WADA-banned

also called — SLU-PP-915 · "915" · orally-active pan-ERR agonist (ERRα/β/γ)

metabolicendurance / aerobic capacity (exercise mimetic)mitochondrial biogenesis / fat oxidation(oral — the differentiator)

The "exercise pill" that fixed its predecessor's fatal flaw — with a pill. SLU-PP-915 is the successor to SLU-PP-332 (#60), and its story is full of intrigue. Three threads: (1) it solves the exact defect that likely doomed #60 — it's the first ERR agonist that actually works orally (its predecessor had to be injected); (2) it's a chemically different molecule that hits the same effect at a lower dose — more efficient by design; (3) the intrigue thickens around it — anti-doping labs are already building detection tests before it's anywhere near humans, and its inventor holds a direct financial stake in companies developing ERR agonists. It's a small molecule, not a peptide — and, like #60, it has zero human data.

In brief

SLU-PP-915 is a small-molecule pan-ERR agonist — an "exercise mimetic" — and the orally-active successor to SLU-PP-332 (#60) from the same lab (Thomas Burris). By activating the estrogen-related receptors (ERRα/β/γ), it switches on genes for mitochondrial biogenesis, fat oxidation, and the Krebs cycle, mimicking the muscle's response to aerobic exercise and boosting endurance in mice. Its whole reason for existing is intrigue #1: its predecessor #60 couldn't be absorbed orally, so the lab engineered 915 — a chemically different molecule (boronic-acid thiophene) that works by mouth at a lower dose, the first ERR agonist to do so. The intrigue deepens: anti-doping labs are already building tests to catch it (as they did for AICAR #64), and its inventor holds equity in companies developing ERR agonists — a declared conflict worth noting. The decisive caveat is unchanged from #60: it's a small molecule (not a peptide), it has zero human data, and it's unapproved. So: a cleverly engineered "exercise pill" that fixed the delivery problem in mice — genuinely interesting chemistry, still entirely preclinical, and already a doping-control target.

Legal standing, by region

European Union

Not FDA-approved (gray-market)

not an approved drug; investigational/research chemical. Not a cosmetic.

⚠ WADA-prohibited in sportSport as an exercise mimetic in the ERR class (alongside SLU-PP-332), it is squarely in anti-doping crosshairs — with detection methods actively under development (see Intrigue #3). Realistically WADA-relevant / prohibited-category territory for the class.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Endurance / exercise capacity (the marketed use)

Real, notable mouse data + oral breakthrough — but no human trials at all

Mouse studies: enhanced running distance/duration; oral efficacy (first for the class); Ddit4 induction; type-IIa fiber shift

F

Oral bioavailability (its whole point vs #60)

The genuine advance over #60 — in mice; says nothing about human PK/safety

Demonstrated oral activity; 7-day dosing without accumulation/tachyphylaxis

B

Metabolic syndrome / heart failure / muscle atrophy / DMD

Interesting breadth, all animal/cell; none established

Preclinical (Billon 2024; Circulation heart-failure work; aging/DMD models)

F

Human efficacy or safety

Zero human data as of 2026

None

F

Doping / sport status

Being built into anti-doping before approval; class is prohibited-category

Detection methods under development (2026)

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for SLU-PP-915 changes - nothing else.

Identity

a synthetic small molecule that activates the estrogen-related receptors (ERRα, ERRβ, ERRγ) — orphan nuclear receptors — to mimic aspects of aerobic exercise ("exercise mimetic"). It is the orally-bioavailable successor to SLU-PP-332 (#60), from the same laboratory, and is a chemically distinct scaffold built specifically to overcome #60's limitations.

Mechanism (as proposed)

the estrogen-related receptors (ERRα/β/γ) are orphan nuclear receptors — structurally related to estrogen receptors but not activated by estrogens — that act as master transcriptional regulators of mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and the Krebs cycle, and are essential for skeletal-muscle adaptation to aerobic exercise. SLU-PP-915 is a pan-agonist (hitting all three, with ERRα central to the effect) that induces Ddit4 — a driver of the acute aerobic-exercise transcriptional program — and thereby increases maximal exercise capacity and oxidative (type-IIa) muscle fibers. The advance over #60 is purely pharmacokinetic-chemical: a new scaffold (boronic-acid thiophene) engineered from ERRγ crystal-structure data to be orally absorbed while preserving the same receptor pharmacology — so the mechanism is shared with #60, but the deliverability (in mice) is new.

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

PubChem CID142532359

InChIKeyCKROIKQTGRZRKF-UHFFFAOYSA-N

SMILESB(C1=CC(=CC=C1)C2=CC=C(S2)C(=O)NC3=CC=CC=C3F)(O)O

ChEMBLCHEMBL5629871

via PubChem exact-name match (SLU-PP-915) · high confidence

Sources — 4 cited

01Billon C, Appourchaux K, Côté I, Burris TP. An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;393(1):103787 (the defining paper: oral activity, distinct scaffold, comparable efficacy at lower dose, Ddit4).

02Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024 (class metabolic effects).

03Avliyakulov NK, Sobolevsky T, Ahrens E. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332… for Doping-Control Purposes. Drug Test Anal. 2026 (anti-doping detection).

04Conflict-of-interest disclosure: SLU-PP-915 IP (Saint Louis University; Burris inventor); Burris stockholder in Myonid Therapeutics and Pelagos Pharmaceuticals. (No human data; not approved as of 2026.)

Updated 2026-07-13 (status: preclinical; the decisive event would be a first-in-human trial — none yet; watch Myonid/Pelagos ERR-agonist pipelines)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

SLU-PP-332 (ERR agonist / "exercise mimetic")F

Small molecule (non-peptide)

AICAR (Acadesine)F

Small molecule (non-peptide)

NAD+ (and its precursors NMN / NR)A

Small molecule (non-peptide)

Explore by goal

Metabolic →Mitochondrial →

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.